The largest Big Pharma investments in China are about much more than just numbers; they tell the story of the fight over the biggest game in town. Each million-dollar headline marks the latest salvo in a struggle to take control of a market that could make or break Big Pharma players. Read the full report >>
Sony ($SNE) and Olympus ($OCPNY) will partner to develop and make new endoscopes and other medical devices, the companies disclosed today.
Japan's Olympus ($OCPNY)--one of the world's biggest makers of endoscope equipment (as well as cameras)--appears close to inking a deal with Sony to gain a badly-needed capital infusion.
New Enterprise Associates has raised $2.6 billion, closing its 14th fund, one of the largest funds of its kind ever raised. NEA will zero in on medical device opportunities, plus biopharmaceutical and healthcare companies
The medical devices/equipment industry attracted $700 million in venture investment during the 2012 second-quarter for 84 deals, according to the new MoneyTree report from PricewaterhouseCoopers and the National Venture Capital Association, based on data from Thomson Reuters .
Medtronic is negotiating with Trivitron Healthcare for a possible equity investment in the Indian medical technology company, the Business Standard reports.
For the second time in two weeks, Italy's Sorin Group has made a targeted effort to diversify its cardiac medical device offerings. Once again, its eyes are on a small U.S. company.
Electronics giant Panasonic wants to pour in between 30 billion yen ($380 million) and 50 billion yen ($635 million) into the company, according to Bloomberg and a Kyodo News story cited by Reuters .
The big message delivered from yesterday's stock market rout was simple: shun risk. Flee to safety. And that kind of investment recipe does not benefit an industry like biotechnology. For biotechs,
In light of all the dour economic news you might be surprised to learn that a small overall loss in the value of biotech investments nevertheless left the industry as the leader in performance among